BNTX

BNTX

USD

BioNTech SE American Depositary Share

$104.780+0.460 (0.441%)

Precio en Tiempo Real

Healthcare
Biotecnología
Alemania

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$104.320

Máximo

$107.000

Mínimo

$104.215

Volumen

0.13M

Fundamentos de la Empresa

Capitalización de Mercado

25.2B

Industria

Biotecnología

País

Germany

Estadísticas de Negociación

Volumen Promedio

0.85M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $81.2Actual $104.780Máximo $129.27

Noticias Relacionadas

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140

HC Wainwright & Co. analyst Robert Burns maintains BioNTech with a Buy and raises the price target from $136 to $140.

Ver más
HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $140
GlobeNewswire

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging

Ver más
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
GlobeNewswire

BioNTech to Host Innovation Series R&D Day on November 11, 2025

MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00

Ver más
BioNTech to Host Innovation Series R&D Day on November 11, 2025
GlobeNewswire

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

MAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the

Ver más
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025
Analyst Upgrades

JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120

JP Morgan analyst Jessica Fye maintains BioNTech with a Neutral and lowers the price target from $121 to $120.

Ver más
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $120
GlobeNewswire

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.